Medicamen Biotech Ltd (BSE: 531146) is a New Delhi, Delhi-based company in the Pharmaceuticals industry. With a market capitalisation of ₹367 Cr, it ranks #2,199 by market cap among the 6,197 Indian listed companies on FinBizNet, and #31 of 63 in Pharmaceuticals. At ₹283.90 (as of 16 Nov 2026), the share price is 36.6% below its 52-week high of ₹447.65 and 33.7% above its 52-week low of ₹212.40. The share price is down 29.5% over one year and up 16.9% over three months.
| Current Price | ₹283.90 |
|---|---|
| Market Cap | ₹367 Cr |
| BSE Code | 531146 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 38 |
| Return on Equity | 4.01% |
| Return on Assets | 2.31% |
| 52-Week Range | ₹212.40 – ₹447.65 |
| 1-Year Price Change | -29.5% |
| 3-Month Price Change | +16.9% |
| Beta (1Y) | 0.63 |
| Dividend Yield | 0.37% |
| Headquarters | New Delhi, Delhi |
| Website | www.medicamen.com |
| Revenue | ₹55 Cr |
|---|---|
| Net Profit | ₹4 Cr |
| Net Margin | 7.5% |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Medicamen Biotech Ltd reported revenue of ₹55 Cr in Q2 FY27, up 16.2% from ₹47 Cr in Q2 FY26 and up 14.5% from ₹48 Cr in Q1 FY27. It posted a net profit of ₹4 Cr for the quarter, against a net profit of ₹2 Cr in Q2 FY26 (up 94.8%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹30 Cr (Q4 FY25) to ₹61 Cr (Q4 FY26). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹55 Cr | ₹4 Cr | 7.5% |
| Q1 FY27 | ₹48 Cr | ₹2 Cr | 3.9% |
| Q4 FY26 | ₹61 Cr | ₹4 Cr | 7.3% |
| Q3 FY26 | ₹47 Cr | ₹2 Cr | 3.5% |
| Q2 FY26 | ₹47 Cr | ₹2 Cr | 4.5% |
| Q1 FY26 | ₹43 Cr | ₹2 Cr | 3.7% |
| Q4 FY25 | ₹30 Cr | ₹2 Cr | 6.3% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 42.57% of Medicamen Biotech Ltd's shares as of Oct 2026, against 40.46% in Dec 2025 (+2.11 percentage points). Delivery averaged 100.0% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, syrups, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarials, vitamins, antibiotics, and supplements, other generics, and pain management. The company was incorporated in 1993 and is based in New Delhi, India.
1. Pharmaceuticals Formulations-This segment engages in the development and manufacture of pharmaceutical products.
1. Pharmaceuticals Formulations-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Medicamen Biotech Ltd | ₹367 Cr | 38 | 4.01% | ₹55 Cr | -29.5% |
Listed by market capitalisation. Ratios are shown for context only.
Medicamen Biotech Ltd is trading at ₹283.90, with a market capitalisation of ₹367 Cr.
Medicamen Biotech Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Medicamen Biotech Ltd has a P/E of 38 and a return on equity of 4.01%.
Medicamen Biotech Ltd is listed on the BSE under the scrip code 531146.
Medicamen Biotech Ltd's share price is down 29.5% over one year and up 16.9% over three months. Its 52-week range is ₹212.40 to ₹447.65.
In Q2 FY27, Medicamen Biotech Ltd reported revenue of ₹55 Cr and net profit of ₹4 Cr (consolidated, parsed from the company's exchange filing).
Medicamen Biotech Ltd reported revenue of ₹55 Cr in Q2 FY27, up 16.2% from ₹47 Cr in Q2 FY26 and up 14.5% from ₹48 Cr in Q1 FY27.
Promoters held 42.57% of Medicamen Biotech Ltd's shares as of Oct 2026, against 40.46% in Dec 2025 (+2.11 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.